NYSEArca - Delayed Quote USD

The Consumer Staples Select Sector SPDR Fund (XLP)

80.88 +0.51 (+0.63%)
At close: November 5 at 4:00 PM EST
81.00 +0.12 (+0.15%)
After hours: 7:58 PM EST
Loading Chart for XLP
DELL
  • Previous Close 80.37
  • Open 80.17
  • Bid 80.91 x 3000
  • Ask 82.00 x 1800
  • Day's Range 80.03 - 80.88
  • 52 Week Range 68.27 - 84.53
  • Volume 5,292,282
  • Avg. Volume 9,261,518
  • Net Assets 17.81B
  • NAV 80.34
  • PE Ratio (TTM) 27.57
  • Yield 2.54%
  • YTD Daily Total Return 13.83%
  • Beta (5Y Monthly) 0.58
  • Expense Ratio (net) 0.09%

In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.

SPDR State Street Global Advisors

Fund Family

Consumer Defensive

Fund Category

17.81B

Net Assets

1998-12-16

Inception Date

Performance Overview: XLP

View More

Trailing returns as of 11/4/2024. Category is Consumer Defensive.

YTD Return

XLP
13.83%
Category
11.21%
 

1-Year Return

XLP
20.16%
Category
18.14%
 

3-Year Return

XLP
6.19%
Category
6.76%
 

People Also Watch

Holdings: XLP

View More

Top 10 Holdings (61.87% of Total Assets)

SymbolCompany% Assets
PG
The Procter & Gamble Company 9.81%
COST
Costco Wholesale Corporation 9.45%
WMT
Walmart Inc. 8.44%
KO
The Coca-Cola Company 6.70%
PEP
PepsiCo, Inc. 5.62%
PM
Philip Morris International Inc. 4.54%
CL
Colgate-Palmolive Company 4.44%
MDLZ
Mondelez International, Inc. 4.43%
MO
Altria Group, Inc. 4.36%
TGT
Target Corporation 4.08%

Sector Weightings

SectorXLP
Healthcare   0.36%
Real Estate   0.00%
Technology   0.00%
Utilities   0.00%
Industrials   0.00%
Energy   0.00%

Recent News: XLP

View More

Research Reports: XLP

View More
  • BUY as company raises earnings guidance

    Biogen is a biotech company that develops, manufactures, and sells therapies for treating neurological and neurodegenerative diseases. The company is the market leader in multiple sclerosis drugs and launched the first approved treatments for spinal muscular atrophy and Alzheimer's disease. The company also sells products that treat plaque psoriasis, non-Hodgkin's lymphoma, lymphocytic leukemia, and rheumatoid arthritis. Current research continues on MS and has expanded to include neuroimmunology, ophthalmology, lupus, and other neuromuscular and movement disorders. Founded in 1978, the company is located in Cambridge, Massachusetts, employs 7,570 people, and is a component of the S&P 500.

    Rating
    Price Target
     
  • It's red, white, blue, and green on Wall Street at midday. The major indices

    It's red, white, blue, and green on Wall Street at midday. The major indices are higher. The 10-year Treasury note is up 5 bps at 4.36%. Oil is up 1% at $72 per barrel. Argus has done historical research and found that November is the best month of the year for stocks. Since 1980, November has been up by an average of 2.1%, above the averages for other months. Performance is even better in election years. In the 11 election-year Novembers since 1980, stocks have climbed, on average, 2.6%.

     
  • Biogen Earnings: Full-Year Guidance Raised; Early Leqembi Sales Encouraging but Uncertainty Remains

    Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

    Rating
    Price Target
     
  • Biogen Still Has Competitive Advantages in Neurology, but Its Moat Looks Narrow

    Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

    Rating
    Price Target
     

Related Tickers